We have assembled specially-fixed and/or frozen ovarian and endometrial carcinomas and have established, by quantitative in situ hybridization analyses, that expression of a transcript complementary to a fms-related probe correlates strongly with aggressive clinical behavior in these two gynecologic malignancies. We propose to extend these investigations further to better characterize the role of these and other oncogenes in the genesis of clinically aggressive ovarian and endometrial neoplasms and to characterize the molecular biology and cellular physiology of the fms-complementary transcript and fms-related growth factor receptor protein product in our clinical material and in ovarian carcinoma-derived cultured cell lines, since this gene product appears to play an important role in ovarian and endometrial carcinogenesis and may be a potential target for """"""""oncogene-specific"""""""" pharmacologic interventions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA047292-02
Application #
3458892
Study Section
Pathology B Study Section (PTHB)
Project Start
1988-04-01
Project End
1993-03-30
Budget Start
1989-04-01
Budget End
1990-03-31
Support Year
2
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Yale University
Department
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520